Market revenue in 2023 | USD 5,972.9 million |
Market revenue in 2030 | USD 9,290.6 million |
Growth rate | 6.5% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer’s disease dementia |
Fastest growing segment | Lewy Body Dementia |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia, Other Indications |
Key market players worldwide | Eisai Co Ltd, Eli Lilly and Co, Novartis AG ADR, Daiichi Sankyo Co Ltd, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Cipla Ltd DR, Sun Pharmaceutical Industries, Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dementia treatment market will help companies and investors design strategic landscapes.
Alzheimer’s disease dementia was the largest segment with a revenue share of 60.08% in 2023. Horizon Databook has segmented the U.S. dementia treatment market based on alzheimer’s disease dementia, vascular dementia, lewy body dementia, frontotemporal dementia (ftd), parkinson disease dementia, other indications covering the revenue growth of each sub-segment from 2018 to 2030.
The dementia treatment market in the U.S. dominated the North America market with a revenue share of 83.5% in 2024, aided by a strong presence of key players, better reimbursement policies, improved healthcare infrastructure, and favorable initiatives undertaken by government & non-government bodies to improve the healthcare services for dementia patients.
For instance, in October 2023, U.S.-based CuraSen Therapeutics announced the initiation of a human clinical trial with a new neurodegenerative disease drug, CST-3056 in the 4th quarter of 2024. The company has received funding of USD 5.8 million from the Alzheimer’s Drug Discovery Foundation.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. dementia treatment market, including forecasts for subscribers. This country databook contains high-level insights into U.S. dementia treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account